Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review

Current Psychiatry Reports

Volumn 18, Issue 3, 2016, Pages 1-16

  Perna, Giampaolo ^a,b,c   Alciati, Alessandra ^a   Riva, Alice ^a   Micieli, Wilma ^a   Caldirola, Daniela ^a  

^a Department of Clinical Neurosciences   (Italy)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Generalized anxiety disorder; Long term; Panic disorder; Pharmacological treatment; Social anxiety disorder

Indexed keywords

AGOMELATINE; ALPRAZOLAM; BENZODIAZEPINE; BIOLOGICAL MARKER; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DELORAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; SERTRALINE; TRIMIPRAMINE; VENLAFAXINE; VORTIOXETINE; ANXIOLYTIC AGENT;

CLINICAL FEATURE; COMORBIDITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM CARE; LOW DRUG DOSE; NEUROBIOLOGY; OUTCOME ASSESSMENT; PANIC; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHORT COURSE THERAPY; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANXIETY DISORDERS; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS; TREATMENT OUTCOME;

EID: 84957591817     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-016-0668-3     Document Type: Review

References (80)

1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84. doi:10.1002/mpr.1359.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (fifth ed.). Arlington: American Psychiatric Association; 2013.
3. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162(6):1179–87. doi:10.1176/appi.ajp.162.6.1179.
4. Berger A, Edelsberg J, Bollu V, Alvir JM, Dugar A, Joshi AV, et al. Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study. BMC Psychiatry. 2011;11:193. doi:10.1186/1471-244X-11-193.
5. Batelaan N, Smit F, de Graaf R, van Balkom A, Vollebergh W, Beekman A. Economic costs of full-blown and subthreshold panic disorder. J Affect Disord. 2007;104(1-3):127–36. doi:10.1016/j.jad.2007.03.013.
6. Wittchen HU, Fuetsch M, Sonntag H, Muller N, Liebowitz M. Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study. Eur Psychiatry. 2000;15(1):46–58.
7. Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004;34(8):1385–94.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-III. Washington, DC: Amer Psychiatric Pub; 1980.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-III-R. Washington, DC: Amer Psychiatric PuB; 1987.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV. Washington, DC: Amer Psychiatric Pub; 1994.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR fourth edition (text revision). 4th ed. Washington, DC: Amer Psychiatric Pub; 2000.
12. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision (ICD-9). http://www.cdc.gov/nchs/icd/icd9.htm.
13. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/icd9cm.htm.
14. Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision (ICD-10). http://www.cdc.gov/nchs/icd/icd10.htm.
15. American Psychiatric Association. Practice Guidelines for the treatment of patients with Panic Disorder. Second ed. American Psychiatric Association; 2009. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_9.aspx
16. Nardi AE, Valenca AM, Freire RC, Amrein R, Sardinha A, Levitan MN, et al. Randomized, open naturalistic, acute treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2011;31(2):259–61. doi:10.1097/JCP.0b013e318210b4ee.
17. Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32(1):120–6. doi:10.1097/JCP.0b013e31823fe4bd.
18. Van Apeldoorn FJ, Van Hout WJ, Timmerman ME, Mersch PP, den Boer JA. Rate of improvement during and across three treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy, selective serotonin reuptake inhibitor or both combined. J Affect Disord. 2013;150(2):313–9. doi:10.1016/j.jad.2013.04.012.
19. Hendriks GJ, Keijsers GP, Kampman M, Oude Voshaar RC, Verbraak MJ, Broekman TG, et al. A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. Acta Psychiatr Scand. 2010;122(1):11–9. doi:10.1111/j.1600-0447.2009.01517.x.
20. Hendriks GJ, Keijsers GP, Kampman M, Hoogduin CA, Oude Voshaar RC. Predictors of outcome of pharmacological and psychological treatment of late-life panic disorder with agoraphobia. Int J Geriatr Psychiatry. 2012;27(2):146–50. doi:10.1002/gps.2700.
21. Choi KW, Woo JM, Kim YR, Lee SH, Lee SY, Kim EJ, et al. Long-term escitalopram treatment in Korean patients with panic disorder: a prospective, naturalistic, open-label, multicenter trial. Clin Psychopharmacol Neurosci. 2012;10(1):44–8. doi:10.9758/cpn.2012.10.1.44.
22. Miniati M, Calugi S, Rucci P, Shear MK, Benvenuti A, Santoro D, et al. Predictors of response among patients with panic disorder treated with medications in a naturalistic follow-up: the role of adult separation anxiety. J Affect Disord. 2012;136(3):675–9. doi:10.1016/j.jad.2011.10.008.
23. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002–8. doi:10.4088/JCP.11m07493.
24. Wetherell JL, Petkus AJ, White KS, Nguyen H, Kornblith S, Andreescu C, et al. Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. Am J Psychiatry. 2013;170(7):782–9. doi:10.1176/appi.ajp.2013.12081104.
25. Mork A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666–75. doi:10.1124/jpet.111.189068.
26. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197–207. doi:10.1097/YIC.0b013e3283530ad7.
27. Kasper S, Iglesias-Garcia C, Schweizer E, Wilson J, DuBrava S, Prieto R, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014;17(5):685–95. doi:10.1017/S1461145713001557.
28. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461–70. doi:10.1177/0269881111405360.
29. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11–24. doi:10.1097/YIC.0b013e32833e34d9.
30. Sheehan DV, Svedsater H, Locklear JC, Eriksson H. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord. 2013;151(3):906–13. doi:10.1016/j.jad.2013.07.037.
31. Endicott J, Svedsater H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301–11. doi:10.2147/NDT.S32320.
32. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ. Time to relapse after 6 and 12 months’ treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010;67(12):1274–81. doi:10.1001/archgenpsychiatry.2010.170.
33. Rickels K, Etemad B, Rynn MA, Lohoff FW, Mandos LA, Gallop R. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR. Psychother Psychosom. 2013;82(6):363–71. doi:10.1159/000351410.
34. Narasimhan S, Aquino TD, Multani PK, Rickels K, Lohoff FW. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2012;198(1):112–5. doi:10.1016/j.psychres.2011.12.034.
35. Cooper AJ, Rickels K, Lohoff FW. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Hum Psychopharmacol. 2013;28(3):258–62. doi:10.1002/hup.2317.
36. Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13(1):21–6. doi:10.1038/tpj.2011.47. The first study showing a role of serotonergic system polymorphisms in long-term treatment response in generalized anxiety disorder.
37. Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13(5):464–9. doi:10.1038/tpj.2012.33.
38. Cooper AJ, Narasimhan S, Rickels K, Lohoff FW. Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2013;210(3):1299–300. doi:10.1016/j.psychres.2013.07.038.
39. Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29(10):1223–30. doi:10.1185/03007995.2013.820694.
40. Ruiz MA, Alvarez E, Carrasco JL, Olivares JM, Perez M, Rejas J. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Des Devel Ther. 2015;9:4329–40. doi:10.2147/DDDT.S88238.
41. Alvarez E, Carrasco JL, Olivares JM, Lopez-Gomez V, Vilardaga I, Perez M. Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: findings from the observational ADAN study. Clin Pract Epidemiol Ment Health. 2012;8:158–68. doi:10.2174/1745017901208010158.
42. Freire RC, Hallak JE, Crippa JA, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother. 2011;12(9):1419–28. doi:10.1517/14656566.2011.562200.
43. Perna G, Guerriero G, Caldirola D. Emerging drugs for panic disorder. Expert Opin Emerg Drugs. 2011;16(4):631–45. doi:10.1517/14728214.2011.628313.
44. Batelaan NM, Van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. Int J Neuropsychopharmacol. 2012;15(3):403–15. doi:10.1017/S1461145711000800.
45. Andersch S, Hetta J. A 15-year follow-up study of patients with panic disorder. Eur Psychiatry. 2003;18(8):401–8.
46. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry. 2004;4:16. doi:10.1186/1471-244X-4-16.
47. National Collaborating Centre for Mental Health. Generalised anxiety disorder in adults: management in primary, secondary and community care. National clinical guideline number 113 ed. Leicester: The British Psychological Society and The Royal College of Psychiatrists; 2011.
48. Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111(27-28):473–80. doi:10.3238/arztebl.2014.0473. Recent recommendations for pharmacological and non-pharmacological treatments in Anxiety Disorders.
49. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders—a meta-analysis. J Affect Disord. 2010;123(1-3):9–16. doi:10.1016/j.jad.2009.06.021.
50. Mavissakalian MR, Perel JM. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry. 2001;13(2):63–7.
51. Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol. 2002;22(3):294–9.
52. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95(2):153–60.
53. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50(1):51–60.
54. Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007;30(6):326–34. doi:10.1097/WNF.0b013e318064579f.
55. Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L. Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol. 2002;22(3):300–8.
56. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001;34(3):85–90. doi:10.1055/s-2001-14283.
57. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006;188:305–12. doi:10.1192/bjp.188.4.305.
58. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds 3rd CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67. doi:10.1002/wps.20089.
59. Deckersbach T, Moshier SJ, Tuschen-Caffier B, Otto MW. Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use. Depress Anxiety. 2011;28(11):999–1007. doi:10.1002/da.20891.
60. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19(3):437–54. doi:10.1016/S0887-6177(03)00096-9.
61. Verdoux H, Lagnaoui R, Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med. 2005;35(3):307–15.
62. Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Salzman C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv. 2003;54(7):1006–11.
63. Nardi AE, Freire RC, Valenca AM, Amrein R, de Cerqueira AC, Lopes FL, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010;30(3):290–3. doi:10.1097/JCP.0b013e3181dcb2f3.
64. Bandelow B, Boerner JR, Kasper S, Linden M, Wittchen HU, Moller HJ. The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int. 2013;110(17):300–9. doi:10.3238/arztebl.2013.0300. quiz 10.
65. Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015;3(1):4. doi:10.1186/s40303-015-0011-7. An updated review, based on clinical trials, non-interventional studies and pharmacovigilance databases, on potential agomelatine-related risk of liver injury.
66. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18–28. doi:10.1097/YIC.0b013e3282f0f0d7.
67. Newcomer JW. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry. 2009;70 Suppl 3:30–6. doi:10.4088/JCP.7075su1c.05.
68. Massion AO, Dyck IR, Shea MT, Phillips KA, Warshaw MG, Keller MB. Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder. Arch Gen Psychiatry. 2002;59(5):434–40.
69. Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2013;16(1):235–49. doi:10.1017/S1461145712000119. A recent review on pharmacological treatments for Social Anxiety Disorder based on placebo-controlled studies and meta-analyses.
70. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203–15. doi:10.2147/NDT.S23317. A systematic literature review and meta-analysis on the evidence-based pharmacological and non-pharmacological treatments for social phobia.
71. Perna G, Schruers K, Alciati A, Caldirola D. Novel investigational therapeutics for panic disorder. Expert Opin Investig Drugs. 2015;24(4):491–505. doi:10.1517/13543784.2014.996286. A recent review on novel mechanism-based anti-panic drugs under current investigation in animal studies up to phase- II studies, with a focus on the translational validity of animal models.
72. Rosnick CB, Rawson KS, Butters MA, Lenze EJ. Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder. Aging Ment Health. 2013;17(4):432–40. doi:10.1080/13607863.2012.761673.
73. Maron E, Nutt D. Biological predictors of pharmacological therapy in anxiety disorders. Dialogues Clin Neurosci. 2015;17(3):305–17.
74. Caldirola D, Perna G. Is there a role for pharmacogenetics in the treatment of panic disorder? Pharmacogenomics. 2015;16(8):771–4. doi:10.2217/pgs.15.66.
75. Shin LM, Davis FC, Vanelzakker MB, Dahlgren MK, Dubois SJ. Neuroimaging predictors of treatment response in anxiety disorders. Biol Mood Anxiety Disord. 2013;3(1):15. doi:10.1186/2045-5380-3-15.
76. Park YM, Kim DW, Kim S, Im CH, Lee SH. The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder. Psychopharmacology (Berl). 2011;213(2-3):625–32. doi:10.1007/s00213-010-2061-y.
77. Lenze EJ, Dixon D, Mantella RC, Dore PM, Andreescu C, Reynolds 3rd CF, et al. Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder. Int J Geriatr Psychiatry. 2012;27(5):454–62. doi:10.1002/gps.2732.
78. Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J Clin Psychopharmacol. 2010;30(6):672–7.
79. Perlis RH, Fijal B, Dharia S, Houston JP. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J. 2013;13(3):280–5. doi:10.1038/tpj.2011.62.
80. Vidyasagar M. Identifying predictive features in drug response using machine learning: opportunities and challenges. Annu Rev Pharmacol Toxicol. 2015;55:15–34. doi:10.1146/annurev-pharmtox-010814-124502.